Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KPTI
KPTI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KPTI News
Biotech Landscape Update: Regulatory Approvals and Mergers
3d ago
NASDAQ.COM
KPTI Shares Drop in Pre-Market Trading Despite Karyopharm's Myelofibrosis Treatment Achieving Key Goal — Retail Investors Skeptical of FDA Approval
6d ago
stocktwits
Karyopharm Seeks Label Expansion for Xpovio After Positive Trial Results
6d ago
seekingalpha
Karyopharm Therapeutics Secures $30M Private Placement
6d ago
seekingalpha
Karyopharm Reports Significant Results from SENTRY Trial for Myelofibrosis
6d ago
PRnewswire
Karyopharm Secures $30 Million in Private Placement Financing
6d ago
PRnewswire
Karyopharm Secures $30 Million in Private Placement Financing
6d ago
Newsfilter
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 10 2026
Benzinga
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
Feb 17 2026
Newsfilter
Karyopharm Therapeutics Q4 2025 Earnings Call Highlights
Feb 13 2026
seekingalpha
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
Feb 12 2026
NASDAQ.COM
Karyopharm Q4 Earnings Beat Expectations, 2026 Outlook Positive
Feb 12 2026
seekingalpha
Karyopharm Reports 2025 Financial Results and 2026 Outlook
Feb 12 2026
PRnewswire
Karyopharm Reports 2025 Financials and 2026 Outlook
Feb 12 2026
Newsfilter
Karyopharm Therapeutics to Announce Q4 Earnings on February 12
Feb 11 2026
seekingalpha
Wall Street Analysts Adjust Ratings
Feb 05 2026
Benzinga
Show More News
